Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
suvemcitug + paclitaxel
- Development stage
- Phase 3
- Lead developer
- Epitomics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Suvemcitug + paclitaxel is a combination therapy consisting of suvemcitug (brand name Enzeshu), a recombinant humanized anti-VEGF rabbit monoclonal antibody, and paclitaxel, a microtubule-stabilizing taxane chemotherapy. Suvemcitug selectively binds to multiple isoforms of vascular endothelial growth factor A (VEGFA), including VEGF121, VEGF165, VEGF164, and VEGF189, thereby blocking their interaction with VEGFR1 and VEGFR2 to inhibit tumor angiogenesis and growth. Paclitaxel is a cytotoxic small molecule that binds to the beta subunit of tubulin, promoting microtubule assembly and stabilizing them against depolymerization, which disrupts mitotic spindle dynamics and induces cell cycle arrest and apoptosis. This combination is approved in China for the treatment of adult patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer who have received no more than one prior line of systemic therapy.
- Other names
- APX-003 + paclitaxelBD-0801 + paclitaxelEnzeshu + paclitaxelsevacizumab + paclitaxelsuvemcitug plus paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on suvemcitug + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on suvemcitug + paclitaxel.